The amazing and very positive thing is amrn keeping 50 percent of the market. It is near impossible for a single drug company to compete with generics. The bundling they do with pbms putting the generic in a higher tier and then giving discounts on drug a and b makes it near impossible for any drug company. So they are definitely buying time to figure out a long term solution. I do not believe the company will be sold in the near term. Not because sarissa or stockholders dont want to sell it more because the stock will not fetch the value they expect. Last year bio had an excellent year in m and a. The average premium was 84 percent. People hear are talking thousands of percent. By the way my history with amrn is around 20 years. First was a huge win bought in the 2 and 3s was down hugr for years and sold all at 16. Over the last 10 have lost on every share and option purchase. Bought back around 10 I did have puts covering my long pos when we lost the patent covering 80 percent of my losses. Sold everything the next day at 4. At least 20 trades since all losers.
with reference to your comment: "although the new formulation hasn't even yet gotten a full patent". When do you think the full patent for the new formulation will be approved? It has been a while now since we have heard any news about it?
Market Data 
Markets 
AI
